| Stanley Chase Grandon, MD | |
|
15212 Michigan Ave, Dearborn, MI 48126-3497 | |
| (313) 582-8856 | |
| (313) 582-8265 |
| Full Name | Stanley Chase Grandon |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 15212 Michigan Ave, Dearborn, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013956556 | NPI | - | NPPES |
| 1382517 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | SG030076 (Michigan) | Primary |
| Entity Name | Associated Eye Physicians Of Dearborn Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386711547 PECOS PAC ID: 5799732533 Enrollment ID: O20050405000219 |
News Archive
Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
Year-old changes to the system that distributes deceased donor kidneys nationwide have significantly boosted transplantation rates for black and Hispanic patients on waiting lists, reducing racial disparities inherent in the previous allocation formula used for decades, according to results of research led by a Johns Hopkins transplant surgeon.
Today, the U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss (alopecia) in female breast cancer patients undergoing chemotherapy.
The University of Texas MD Anderson Cancer Center and the Houston Independent School District have reached a first-of-its-kind agreement to provide access to an evidence-based, youth-oriented tobacco prevention and cessation program for all 110,000 HISD middle and high school students.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stanley Chase Grandon, MD 15212 Michigan Ave, Dearborn, MI 48126-3497 Ph: (313) 582-8856 | Stanley Chase Grandon, MD 15212 Michigan Ave, Dearborn, MI 48126-3497 Ph: (313) 582-8856 |
News Archive
Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
Year-old changes to the system that distributes deceased donor kidneys nationwide have significantly boosted transplantation rates for black and Hispanic patients on waiting lists, reducing racial disparities inherent in the previous allocation formula used for decades, according to results of research led by a Johns Hopkins transplant surgeon.
Today, the U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss (alopecia) in female breast cancer patients undergoing chemotherapy.
The University of Texas MD Anderson Cancer Center and the Houston Independent School District have reached a first-of-its-kind agreement to provide access to an evidence-based, youth-oriented tobacco prevention and cessation program for all 110,000 HISD middle and high school students.
› Verified 8 days ago
Dr. Kyle Welburn, DO Ophthalmology Medicare: Medicare Enrolled Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-593-7000 | |
Dr. Asheesh Tewari, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 25230 Michigan Ave, Dearborn, MI 48124 Phone: 134-412-2273 Fax: 313-441-2241 | |
Donald C Fiander, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 25325 Ford Rd, Suite 200, Dearborn, MI 48128 Phone: 313-357-3006 Fax: 313-724-2455 | |
Inna Bondira, DO Ophthalmology Medicare: Medicare Enrolled Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-593-7000 | |
John Denis Roarty, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 22731 Newman, Suite 245, Dearborn, MI 48124 Phone: 313-561-1777 Fax: 313-561-8044 | |
James Matthew Todaro, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-593-7000 |